Snapshot
A US biotech company commissioned COUCH Health to help improve the representation of African American communities in their phase 3 study for a new heart disease treatment.
Improving African American representation in the clinical trial was crucial given the population’s higher prevalence of heart disease.
Problem
Historically, African Americans are disproportionately affected by heart disease, yet they remain significantly underrepresented in clinical trials.
This underrepresentation is compounded by deep-rooted mistrust of the medical system due to past injustices and ethical breaches, as well as logistical and socioeconomic barriers that make it difficult for African Americans to participate in clinical trials.
It was crucial for African Americans to be involved in the clinical study to ensure the study population accurately represented those living with heart disease and that the treatment’s efficacy and safety were studied in all patient populations.
Nearly 48% of African American women and 44% of African American men have some form of heart disease.
African Americans are 30% more likely to die from heart disease than non-Hispanic whites.
Strategy
COUCH Health initiated an engagement strategy comprising 3 key components with the aim of improving African American participation in the clinical study.
1. Community partnerships
Collaborate with community groups across the US, such as the Association of Black Cardiologists, to help build trust and raise awareness.
2. Cultural ambassadors
Train community leaders to communicate the benefits of participating in clinical research and address any concerns.
3. Education and outreach
Run informational sessions and health fairs to educate potential participants about heart disease and the importance of clinical trials.
